21 – 30 of 32
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Adjuvant chemotherapy in endometrial cancer.
(
- Contribution to journal › Article
-
Mark
Characterisation Of The Hepatic Safety Profile Of Trabectedin: Pooled Analysis Of 19 Phase II Clinical Trials (CTS) In 1132 Patients With Solid Tumours
2010) 35th European-Society-for-Medical-Oncology (ESMO) Congress In Annals of Oncology 21(Suppl. 8). p.177-178(
- Contribution to journal › Published meeting abstract
-
Mark
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - Results from two randomised studies
(
- Contribution to journal › Article
- 2008
-
Mark
Adjuvant Chemotherapy in Endometrial Carcinoma: Overview of Randomised Trials.
(
- Contribution to journal › Article
- 2007
-
Mark
Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.
(
- Contribution to journal › Article
- 2006
-
Mark
Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits
(
- Contribution to journal › Article
- 2002
-
Mark
Med P:n som i programpaket. Om datatortyr och signifikansfiskeri
(
- Contribution to journal › Article
-
Mark
High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.
(
- Contribution to journal › Article
- 2001
-
Mark
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer
(
- Contribution to journal › Article
- 1997
-
Mark
Identification of TP53 gene mutations in uterine corpus cancer with short follow-up
(
- Contribution to journal › Article